Replies to post #234243 on Biotech Values

[DewDiligence]

FDA places clinical hold on SNY’s Tolebrutinib trials:

https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-30-05-30-00-2471767

Tolebrutinib is the BTK inhibitor SNY picked up in the $3.4B 2020 buyout of Principia Biopharma (#msg-157669162).

[DewDiligence]

SNY scraps topical-BTK program acquired in 2020 buyout of PRNB for $3.4B:

https://endpts.com/sanofi-scraps-topical-btk-drug-from-3-7b-principia-buyout/